FerroptoCure Inc.

FerroptoCure Inc. is a clinical-stage biotechnology company founded in 2022 that focuses on developing novel anti-cancer therapeutics by inducing ferroptosis, an iron-dependent form of cell death. The company leverages advanced technologies, including next-generation sequencing, data informatics, and in silico analysis, to manipulate cellular antioxidant mechanisms such as the xCT subunit. By inhibiting these pathways, FerroptoCure aims to overcome cancer resistance to conventional therapies. Their approach is rooted in extensive research originating from Keio University, targeting not only various neoplasms but also potential applications for neurodegenerative disorders and hepatitis. The company is actively expanding its research efforts, including the development of treatments for companion animals.

These therapeutic innovations address the significant clinical need for safe and effective treatments for drug-resistant cancers, which are often highly sensitive to ferroptosis-inducing interventions. The company is currently advancing its clinical pipeline, with its lead project having completed a Phase 1a trial in Japan. Supported by venture capital and government research grants, FerroptoCure is scaling its organizational structure and pursuing global expansion strategies, including the establishment of an Australian subsidiary and participation in international biotechnology partnerships to facilitate out-licensing and further development.